Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christine Guo Lian, M.D.

Co-Author

This page shows the publications co-authored by Christine Lian and George Murphy.
Connection Strength

5.715
  1. The Genetic Evolution of Melanoma. N Engl J Med. 2016 03 10; 374(10):994-5.
    View in: PubMed
    Score: 0.654
  2. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Mod Pathol. 2014 Jun; 27(6):788-99.
    View in: PubMed
    Score: 0.564
  3. ATF-3 expression inhibits melanoma growth by downregulating ERK and AKT pathways. Lab Invest. 2021 05; 101(5):636-647.
    View in: PubMed
    Score: 0.227
  4. Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation. J Invest Dermatol. 2020 06; 140(6):1266-1275.e3.
    View in: PubMed
    Score: 0.212
  5. Differential distribution of the epigenetic marker 5-hydroxymethylcytosine occurs in hair follicle stem cells during bulge activation. J Cutan Pathol. 2019 May; 46(5):327-334.
    View in: PubMed
    Score: 0.202
  6. Reversal of TET-mediated 5-hmC loss in hypoxic fibroblasts by ascorbic acid. Lab Invest. 2019 07; 99(8):1193-1202.
    View in: PubMed
    Score: 0.201
  7. Chronic rejection of human face allografts. Am J Transplant. 2019 04; 19(4):1168-1177.
    View in: PubMed
    Score: 0.197
  8. Biological significance of 5-hydroxymethylcytosine in oral epithelial dysplasia and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jan; 125(1):59-73.e2.
    View in: PubMed
    Score: 0.179
  9. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. J Cutan Pathol. 2017 Mar; 44(3):249-255.
    View in: PubMed
    Score: 0.174
  10. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. Lab Invest. 2017 02; 97(2):207-216.
    View in: PubMed
    Score: 0.172
  11. Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab). J Cutan Pathol. 2016 Nov; 43(11):989-993.
    View in: PubMed
    Score: 0.169
  12. TET2 Negatively Regulates Nestin Expression in Human Melanoma. Am J Pathol. 2016 06; 186(6):1427-34.
    View in: PubMed
    Score: 0.165
  13. Epigenetic markers in melanoma. Melanoma Manag. 2015 Nov; 2(4):367-382.
    View in: PubMed
    Score: 0.160
  14. Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma. Oncotarget. 2015 Nov 10; 6(35):37995-8004.
    View in: PubMed
    Score: 0.160
  15. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics. 2015; 7:59.
    View in: PubMed
    Score: 0.155
  16. Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update. Dermatopathology (Basel). 2015 Jan-Mar; 2(1):15-42.
    View in: PubMed
    Score: 0.153
  17. Novel genetic mutations in a sporadic port-wine stain. JAMA Dermatol. 2014 Dec; 150(12):1336-40.
    View in: PubMed
    Score: 0.150
  18. Nestin depletion induces melanoma matrix metalloproteinases and invasion. Lab Invest. 2014 Dec; 94(12):1382-95.
    View in: PubMed
    Score: 0.149
  19. Decrease of 5-hydroxymethylcytosine in rat liver with subchronic exposure to genotoxic carcinogens riddelliine and aristolochic acid. Mol Carcinog. 2015 Nov; 54(11):1503-7.
    View in: PubMed
    Score: 0.147
  20. 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Mod Pathol. 2015 Feb; 28(2):218-29.
    View in: PubMed
    Score: 0.146
  21. Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest. 2014 Aug; 94(8):822-38.
    View in: PubMed
    Score: 0.145
  22. Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors. Mod Pathol. 2014 Jul; 27(7):936-44.
    View in: PubMed
    Score: 0.141
  23. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012 Sep 14; 150(6):1135-46.
    View in: PubMed
    Score: 0.128
  24. Full facial retransplantation in a female patient-Technical, immunologic, and clinical considerations. Am J Transplant. 2021 10; 21(10):3472-3480.
    View in: PubMed
    Score: 0.059
  25. PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 2021 01 04; 218(1).
    View in: PubMed
    Score: 0.057
  26. Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation. J Plast Reconstr Aesthet Surg. 2021 Jul; 74(7):1562-1571.
    View in: PubMed
    Score: 0.057
  27. Mucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review. Transplantation. 2020 12; 104(12):2616-2624.
    View in: PubMed
    Score: 0.057
  28. Accelerated chronic skin changes without allograft vasculopathy: A 10-year outcome report after face transplantation. Surgery. 2020 06; 167(6):991-998.
    View in: PubMed
    Score: 0.054
  29. Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Sci Rep. 2018 10 08; 8(1):14915.
    View in: PubMed
    Score: 0.049
  30. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 2018 07; 559(7715):637-641.
    View in: PubMed
    Score: 0.048
  31. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer. J Biol Chem. 2018 07 13; 293(28):11166-11178.
    View in: PubMed
    Score: 0.048
  32. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 04 19; 173(3):624-633.e8.
    View in: PubMed
    Score: 0.047
  33. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clin Cancer Res. 2018 03 15; 24(6):1389-1401.
    View in: PubMed
    Score: 0.046
  34. Longitudinal immunological characterization of the first presensitized recipient of a face transplant. JCI Insight. 2017 Jul 06; 2(13).
    View in: PubMed
    Score: 0.045
  35. Face Transplantation in a Highly Sensitized Recipient. Mil Med. 2016 10; 181(10):1392.
    View in: PubMed
    Score: 0.043
  36. Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas. Melanoma Res. 2016 10; 26(5):524-7.
    View in: PubMed
    Score: 0.043
  37. Face Transplantation in a Highly Sensitized Recipient. Mil Med. 2016 05; 181(5 Suppl):221-6.
    View in: PubMed
    Score: 0.041
  38. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016 Apr 08; 352(6282):189-96.
    View in: PubMed
    Score: 0.041
  39. Codominant Role of Interferon-?- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients. Am J Transplant. 2016 07; 16(7):2158-71.
    View in: PubMed
    Score: 0.041
  40. Transformation of Face Transplants: Volumetric and Morphologic Graft Changes Resemble Aging After Facial Allotransplantation. Am J Transplant. 2016 Mar; 16(3):968-78.
    View in: PubMed
    Score: 0.040
  41. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015 Sep 10; 162(6):1242-56.
    View in: PubMed
    Score: 0.039
  42. Acute rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant. 2014 Dec; 19(6):531-44.
    View in: PubMed
    Score: 0.037
  43. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant. 2014 Jun; 14(6):1446-52.
    View in: PubMed
    Score: 0.036
  44. Abstract 59: face transplantation in a highly sensitized recipient. Plast Reconstr Surg. 2014 Apr; 133(4 Suppl):1021.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.